SCHEDULE: Eli Lilly Discloses 11.9% Stake in Aktis Oncology Post-IPO
Schedule 13D Filing
Eli Lilly and Company has reported a significant 11.9% beneficial ownership in Aktis Oncology, Inc. following its initial public offering.
Summary
- Eli Lilly and Company beneficially owns 6,344,114 shares of Aktis Oncology, Inc. Common Stock.
- This ownership represents approximately 11.9% of Aktis Oncology's issued and outstanding Common Stock, based on 53,296,950 shares outstanding as of January 14, 2026.
- The shares were acquired through a combination of pre-IPO investments and a significant purchase in Aktis Oncology's initial public offering (IPO).
- Eli Lilly acquired 788,559 shares upon conversion of Series A-1 Preferred Stock ($10.0 million) and Series B Preferred Stock ($2.0 million) prior to the IPO.
- An additional 5,555,555 shares of Common Stock were purchased in the IPO at $18.00 per share, totaling approximately $100.0 million.
- The total investment by Eli Lilly in Aktis Oncology, including pre-IPO and IPO purchases, amounts to approximately $112.0 million.
- Eli Lilly states its purpose for acquiring the securities is for investment purposes and intends to review its investment on an ongoing basis.
- The reporting person has entered into an Investors' Rights Agreement, granting customary registration rights, and a lock-up agreement restricting sales for 180 days after January 8, 2026.
Sentiment
Score: 8
Explanation: The sentiment is positive as a major pharmaceutical company, Eli Lilly, has made a substantial strategic investment in Aktis Oncology, indicating confidence in the company's future. This provides significant capital and validation for Aktis Oncology.
Positives
- Eli Lilly's significant investment of approximately $112.0 million demonstrates strong confidence in Aktis Oncology's potential.
- The 11.9% stake by a major pharmaceutical company like Eli Lilly can provide strategic validation and potentially attract further institutional interest in Aktis Oncology.
- The Investors' Rights Agreement provides Eli Lilly with customary registration rights, offering flexibility for future liquidity if needed.
Negatives
- Eli Lilly is subject to a 180-day lock-up agreement, restricting the sale or transfer of its shares until approximately July 2026, which limits immediate liquidity for this large shareholder.
Risks
- Eli Lilly may, at any time, acquire additional shares or dispose of any or all of its shares, which could impact Aktis Oncology's stock price stability.
- The lock-up agreement restricts Eli Lilly from selling shares for 180 days, but after this period, a large block of shares could potentially enter the market, creating downward pressure.
Future Outlook
Eli Lilly acquired the securities for investment purposes and plans to continuously review its investment in Aktis Oncology. It may, at its discretion, acquire additional shares, dispose of existing shares, or engage in hedging transactions. Eli Lilly also expects to engage in discussions with Aktis Oncology's management and other stakeholders regarding operational, financial, and strategic initiatives.
Industry Context
Eli Lilly and Company is a global pharmaceutical leader, and its significant investment in Aktis Oncology, a newly public company in the oncology space, highlights the ongoing strategic interest of large pharma in innovative biotechnology firms. This move aligns with broader industry trends of established players seeking to expand their pipelines and capabilities through strategic investments and partnerships in specialized therapeutic areas like oncology.
Comparison to Industry Standards
- NA This filing details a specific investment and ownership stake, not operational or financial performance metrics that can be directly compared to industry standards or specific comparable companies/projects.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Agreement | Eli Lilly and Company, along with other stockholders, entered into a Third Amended and Restated Investors' Rights Agreement with Aktis Oncology. This agreement provides customary registration rights (demand, piggyback, and shelf registration) under the Securities Act of 1933. | 2024-09-20 | Grants Eli Lilly the ability to require Aktis Oncology to register its shares for public sale, facilitating potential future liquidity. Aktis Oncology is required to cover related expenses, subject to conditions. These rights terminate upon certain liquidation events, ownership falling below 1% with Rule 144 eligibility, or the third anniversary of the IPO. |
| Agreement | Eli Lilly and Company entered into a lock-up agreement, agreeing not to sell or transfer Common Stock or convertible securities for 180 days after January 8, 2026, without the consent of the underwriters. | 2026-01-08 | Restricts Eli Lilly's ability to sell its significant stake for a defined period, which is standard practice post-IPO to stabilize the stock price. This temporarily limits Eli Lilly's liquidity but provides short-term price stability for Aktis Oncology. |
Related Party Transactions
- Eli Lilly's pre-IPO investments in Series A-1 and Series B Preferred Stock, and its participation in the IPO, represent significant transactions with Aktis Oncology, establishing Eli Lilly as a major shareholder.
- Eli Lilly is a party to the Third Amended and Restated Investors' Rights Agreement with Aktis Oncology and certain other stockholders, which governs registration rights and other shareholder matters.
Stakeholder Impact
- Shareholders of Aktis Oncology: Eli Lilly's substantial investment provides a strong vote of confidence and capital, potentially enhancing the company's valuation and stability. However, the potential for future large-scale dispositions by Eli Lilly after the lock-up period could introduce volatility.
- Eli Lilly Shareholders: The investment represents a strategic move into the oncology space, potentially offering future returns and pipeline expansion opportunities for Eli Lilly.
Next Steps
- Eli Lilly will continue to review its investment in Aktis Oncology on an ongoing basis.
- Eli Lilly may engage in discussions with Aktis Oncology's directors, officers, management, and other stakeholders regarding operational, financial, and strategic initiatives.
- Eli Lilly may, at its discretion, acquire additional shares, dispose of existing shares, or engage in hedging or other transactions with respect to Aktis Oncology securities.
Key Dates
| Date | Description |
|---|---|
| 2024-09-20 | Date of Third Amended and Restated Investors' Rights Agreement. |
| 2026-01-07 | Filing date of Aktis Oncology's Registration Statement on Form S-1 (SEC File No. 333-292283). |
| 2026-01-08 | Start date of the 180-day lock-up period for Eli Lilly. |
| 2026-01-09 | Filing date of Aktis Oncology's Prospectus pursuant to Rule 424(b)(4) for its IPO. |
| 2026-01-12 | Date of event requiring the filing of this statement (closing of Aktis Oncology's initial public offering and conversion of preferred stock). |
| 2026-01-13 | Date of press release issued by Aktis Oncology disclosing the full exercise of underwriters' option. |
| 2026-01-14 | Date used for calculating outstanding shares (53,296,950) for ownership percentage. |
| 2026-01-15 | Date of signature for the Schedule 13D filing by Eli Lilly and Company. |
Keywords
Aktis Oncology, Eli Lilly, Schedule 13D, Beneficial Ownership, IPO, Common Stock, Pharmaceuticals, Biotechnology, Investment, Oncology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.